Vitamin K follow-up, a compression comparison, pregnancy data on ivermectin and a wearable sweat test place four findings at different distances from clinical decisions.
Science··Midday
Established care was examined through two kinds of data
Sweden's birth data from 2003 to 2021 compared infants who did not receive intramuscular vitamin K at birth with those who did over their first six months. Among more than two million births, the 24,089 instances of non-receipt were associated with an adjusted odds ratio of 1.52 for any bleeding diagnosis and 2.91 for intracranial haemorrhage; non-receipt also rose from 0.66% in 2006 to 1.50% in 2021. That observational association cannot by itself separate differences such as families' other care choices. VenUS 6 in the United Kingdom directly compared different ways of delivering an established treatment. Its 637 participants at 33 sites were allocated to compression wraps, a two-layer bandage or established strong-compression options. Healing at twelve months was 76.2%, 80.1% and 79.4% respectively, and wraps did not speed healing. Because 71% of participants received a compression treatment other than their allocation at some point and fewer healing events occurred than expected, the size of the difference between groups remains less certain.[1], [2]
A safety follow-up and a diagnostic platform
A prospective follow-up nested within malaria trials in Mozambique and Kenya tracked 129 women inadvertently exposed to ivermectin at the very start of pregnancy and 109 who received albendazole. A composite of miscarriage, stillbirth and major congenital anomaly occurred in 22.9 percent of the ivermectin group and 19.5 percent of the comparator group, a difference that was not statistically significant. Although presented as the largest published prospective ivermectin follow-up, it is not large enough to exclude rare harms or change recommendations. The CF SWIFT study reports a development at another stage: a first adhesive patch uses a small lithium-polymer battery and pilocarpine iontophoresis to induce sweat, a second collects sweat from the same spot, and chloride concentration is read from a colour change. 55 people aged from 14 days to 21 years were measured with both platforms; mean bias was 0.43 millimolar and limits of agreement were about plus or minus 12 millimolar. Only two participants were under 12 months and none was under one month. Multicentre neonatal validation and regulatory clearance are still needed before clinical use.[3], [4]
The findings occupy different points on one path
Read together, the four reports show that a clinical agenda consists of more than new treatments. The vitamin K study follows instances in which an established preventive practice was not delivered across long-running national data; VenUS 6 compares three routes to the same compression goal under everyday care conditions. The ivermectin follow-up extracts safety information from inadvertent exposures rather than from a treatment trial designed around pregnancy. CF SWIFT combines stimulation, sample collection and measurement at one point on the skin in an attempt to make a standard diagnostic process more portable. Each finding therefore corresponds to a different kind of change: the first two inform delivery and selection within existing care, the third narrows a limited safety gap, and the fourth tests a more accessible form of a standard measurement. No single result carries an entire clinical decision. Together, however, these studies make concrete what new information is available at distinct health-care thresholds, from uptake and treatment choice to accidental exposure and diagnostic access.[1], [2], [3], [4]
Related columns
For more information on this topic, you can read the related columns.
